Amicus Therapeutics Inc FOLD
Morningstar.com growth grade = A
Projected Annual Return = 22.3%
June 21, 2021 price = $10.02
Company Profile
Business Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
SectorHealthcare
IndustryBiotechnology
Most Recent EarningsMar 31, 2021
Fiscal Year EndDec 31, 2021
Stock TypeSpeculative Growth
Employees483
No comments:
Post a Comment